SH3 domains regulate many normal and pathological cellular processes by guiding specific protein interactions. Studies on binding of HIV-1 Nef to the SH3 domain of the Hck tyrosine kinase have indicated an important role for the SH3 RT-loop region in ligand binding. Here we have tested the potential of artificial Hck-derived SH3 domains carrying tailored RT-loops providing high affinity for Nef as intracellular inhibitors of Nef. These artificial SH3 domains efficiently associated with Nef in cells and thereby potently inhibited SH3-dependent Nef functions, such as association with p21-activated kinase-2 and induction of the transcription factor NFAT. On the other hand, biochemical and functional data indicated that the Nef-targeted SH3 domains were not prone to compete with normal SH3-mediated processes. Thus, RT-loop-modified SH3 domains represent a novel approach for selectively interfering with cellular signaling events, which could be exploited in research as well as in therapeutic applications.
INTRODUCTION
Many aspects of cell behavior are controlled by dynamic and ordered proximity of cellular proteins. During evolution several different types of protein interaction domains specialized in mediating such regulated and specific protein-protein communication have emerged. The SH3 domain was first identified as a region of homology among the Src family tyrosine kinases (Cohen et al., 1995; Dalgarno et al., 1997; Sudol, 1998) . Thereafter SH3 domains have been noticed in a large number of proteins, and a total of 63 SH3 domains were found in the fruit fly genome (Rubin et al., 2000) , while more than 200 human proteins with SH3 domains can currently be found from the SwissProt database (using SMART; Schultz et al., 1998) . Because SH3 domains often serve functions in the regulation of cell growth and differentiation they are intimately involved in the pathogenesis of diseases such as cancer. In addition, a number of microbial pathogens, such as HIV, exploit SH3-mediated processes as a part of their life cycle (Bliska, 1996; Saksela et al., 1995) .
SH3 domains are small (55-70 amino acids) modular protein units, which mediate inter-and intramolecular protein interactions by binding to ligands that contain a region with a secondary structure known as the polyproline type II (PPII) helix (Kuriyan and Cowburn, 1997; Mayer and Gupta, 1998) . Sequence variation in the PPII helix region of the ligand (the "PxxP motif") can influence the specificity in SH3/ligand complex formation. However, work on HIV-1 Nef/SH3 interactions has demonstrated that a major contribution for binding affinity and specificity is provided by molecular contacts outside the SH3/PxxP interface (Lee et al., 1995 (Lee et al., , 1996 . Specifically, an SH3 structure known as the RT-loop, which is highly divergent among the otherwise similar SH3 domains, can play a key role in determining the ligand binding properties of individual SH3 domains.
In a previous study (Hiipakka et al., 1999) we have exploited the latter concept to engineer artificial SH3 domains with novel specificities and high binding affinities. This was done by using phage display to select clones from large libraries of SH3 domains in which six nonconserved residues in the RT-loop of Hck-SH3 had been substituted by random amino acid combinations. Using this approach we have developed a panel of artificial SH3 domains (termed RRT-SH3 for randomized RTloop) that bind to HIV-1 Nef with unnaturally high binding affinities (K D values in the order of 10 Ϫ8 to 10 Ϫ9 M compared to 10 Ϫ3 to 10 Ϫ6 M for most natural SH3 interactions; Hiipakka et al., 1999) .
Inspired by experiments in which recombinant singlechain antibodies (ScFv's) have been expressed in mammalian cells to inhibit or relocalize cellular target proteins (Chames and Baty, 2000; Hudson, 1999) , in this study we have examined the potential of our Nef-targeted RRT-SH3 domains to serve as intracellular inhibitors of Nef. We show that the high binding affinity of these artificial SH3 domains in vitro is indeed reflected by efficient complex formation with Nef expressed in cells and that this binding results in potent inhibition of SH3-dependent cellular functions of Nef. Importantly, the majority of cellular proteins that coprecipitated with native Hck-SH3 did not associate with the Nef-targeted RRT-SH3 domains. These data highlight the importance of the RT-loop in SH3 ligand recognition and demonstrate the feasibility of this novel approach for interfering with SH3-mediated intracellular processes.
RESULTS

RRT-SH3s associate efficiently with Nef in cotransfected cells
Our previous studies have demonstrated a critical role for the SH3 domain RT-loop region in ligand binding (Lee et al., 1995 (Lee et al., , 1996 . To exploit this concept experimentally we have developed artificial Hck-derived SH3 domains (RRT-SH3s) that can bind their target proteins more selectively and with higher affinities than natural SH3 domains (Hiipakka et al., 1999) . In simple biochemical test systems RRT-SH3s engineered to bind to HIV-1 Nef showed affinities with dissociation constants (K D ) lower than 10 Ϫ8 M. Thus, the strength of these interactions is in the range characteristic of affinity of antibody-antigen binding rather than SH3-mediated interactions (Hiipakka et al., 1999) .
This strong affinity led us to examine if our tailored SH3 domains could serve as specific inhibitors of intracellular functions of Nef. For this purpose five RRT-SH3s targeted for Nef were subcloned into a mammalian expression vector (Fig. 1) . To facilitate detection and purification they were expressed as GST-SH3 fusion proteins, as an N-terminal GST moiety had previously been found not to affect their in vitro binding properties (Hiipakka et al., 1999) . Translation of this fusion protein was engineered to start from a 14-amino-acid myristoylated N-terminal sequence of v-Src placed in front of the GST reading frame. This was done to enhance localization of the GST-SH3 domains on cellular membranes (where most of myristoylated Nef protein resides), but is not expected to exclude this fusion protein from other subcellular compartments. In addition, an HA-epitope tag was appended to the carboxy termini of these constructs. A similarly designed plasmid expressing the Hck-SH3 domain was also constructed. Although much weaker than RRT-SH3/Nef binding, the interaction between Hck-SH3 and Nef is among the tightest of the known natural SH3-mediated protein interactions (K D value 0.2 M; Lee et al., 1995) . As a negative control, a similar expression vector for GST was also made.
To examine the ability of these GST-SH3 fusion proteins to bind to Nef in mammalian cells they were cotransfected with Nef into 293T cells. Forty-eight hours after transfection the cells were lysed, and the GST or GST-SH3 proteins were captured by glutathione Sepharose beads. After extensive washing the proteins that remained associated with the beads were examined by SDS-PAGE and Western blotting. Small aliquots of the lysates were removed before the glutathione affinity selection step and used to examine the expression levels of Nef and GST-SH3 (or empty GST) proteins in the transfected cells.
As shown in Fig. 2A , equal levels of Nef were present in lysates of cells cotransfected with the vectors for GST or GST-SH3, and the latter proteins were also expressed in similar amounts. Accordingly, the amounts of the GST and GST-SH3 proteins (Hck, A1, A2, and B6) captured from these lysates using the glutathione Sepharose beads were also roughly similar (Fig. 2B) . By contrast, the amounts of coprecipitated Nef varied widely. As expected, the GST protein without an SH3 domain did not precipitate any Nef. In agreement with the known affinity of the Hck-SH3 domain for Nef, readily detectable amounts of Nef remained bound to the beads with GSTHck-SH3. However, the RRT-SH3 domains (A1, A2, and B6) were significantly more efficient than Hck-SH3 in associating with Nef.
Although the Western blotting signals specific for the GST-SH3 and Nef proteins detected in parallel using anti-HA and anti-Nef antibodies, respectively, may not be directly comparable, the similar intensities of these signals suggested that the RRT-SH3 domains remained bound to Nef at close to an equimolar ratio. Moreover, when the amount of Nef remaining in the lysates after this GST-SH3 pull-down step was examined, only traces of Nef were detected in lysates of cells that coexpressed the RRT-SH3 domains, whereas in the lysate of the Hck-SH3-expressing cells the amount of Nef was only modestly reduced compared to the original lysate (data not shown). As expected based on our previous in vitro data (Hiipakka et al., 1999) , an SH3 binding-defective Nef mutant unable to bind Hck-SH3 because of alanine substitutions in place of both of the PxxP-motif-defining proline residues (Manninen et al., 1998) failed to associate with the Nef-targeted RRT-SH3 domains in cotransfected cells (Fig. 2 , right panels, and data not shown).
RRT-SH3 domains bind poorly to normal cellular ligands of Hck-SH3
When considering the use of these modified SH3 domains as intracellular inhibitors, it would be desirable that, besides the strong binding to their specific target, they would show minimal binding to the natural substrates of their parental SH3 domains. Because of the intimate involvement of the RT-loop in SH3 ligand selection, changes in the SH3 RT-loop region that increase the affinity for a particular ligand would be expected to conversely decrease binding to other ligands. Thus, we were hopeful that our Nef-targeted RRT-SH3 domains would be deficient in binding to natural partners of Hck. To test this hypothesis we compared the patterns of proteins coprecipitating from cell extracts with wild-type Hck-SH3 or its RRT-SH3 derivatives.
Because Hck is expressed mainly in cells of the myeloid lineage, we used the cell lines U937 and K562 as sources for endogenous Hck-SH3 binding proteins. Since many SH3 ligand proteins are components of cellular signaling cascades, and become tyrosine phosphorylated upon activation of these cascades, we treated the cell lines with the tyrosine phosphatase inhibitor sodium orthovanadate in order to allow sensitive detection of such proteins by anti-phosphotyrosine Western blotting. Equal fractions of these lysates were incubated with recombinant GST or GST-SH3 proteins immobilized to glutathione Sepharose beads. After washing of the beads the bound proteins were separated by SDS-PAGE and subjected to anti-phosphotyrosine immunoblotting (Fig. 3) .
Several proteins in the 40-to 70-kDa size range that were strongly reactive with the anti-phosphotyrosine antibody could be precipitated by the SH3 domains. Some of these appeared to be common to both cell lines (pp54 and pp67), whereas some were preferentially expressed either in U937 (pp44, pp49, and pp51) or in K562 (pp52, pp58, and pp64) cells. This precipitation was SH3-specific, since no anti-phosphotyrosine signal was derived FIG. 3 . RRT-SH3s bind poorly to normal cellular ligands of Hck-SH3. K562 and U937 cells were stimulated with pervanadate before lysis. These lysates were incubated with the indicated recombinant GST-SH3 proteins bound to glutathione Sepharose beads. The associated proteins were resolved by electrophoresis and analyzed by immunoblotting with an anti-phosphotyrosine antibody.
FIG. 2. Efficient intracellular engagement of Nef by RRT-SH3 domains. Lysates of 293T cells transfected with vectors for
Nef and different GST-SH3 proteins (or plain GST) were examined by immunoblotting using anti-Nef and anti-HA or anti-GST antibodies either directly (A, total lysates) or after binding to glutathione Sepharose beads (B, beads). In panels on the left, wild-type Nef was transfected in all cases, whereas in panels on the right wild-type or an SH3 bindingdeficient mutant Nef was used as indicated.
from beads containing an equal amount plain GST (Fig. 3  control) . With the exception of two prominent 58-and 60-kDa phosphotyrosine-containing proteins (pp58 and pp60) that were precipitated by all the SH3 domains from U937 and K562 cell lines, respectively, most of these phosphoproteins were either preferentially or exclusively associated with wild-type Hck-SH3. For example, in both cell lines a major 67-kDa (pp67) tyrosine-phosphorylated protein was seen associated with Hck-SH3, whereas it was recognized much less well by the RRT-SH3 domains A1 and C1, poorly by B6, and not at all by A2. Of the 54/52-kDa doublet precipitated by Hck-SH3 from K562 cells only pp54 was faintly associated with certain RRTSH3s, whereas pp52 was not bound at all. Similarly, the 44-kDa protein (pp44) that gave rise to an intense antiphosphotyrosine signal in the lane containing Hck-SH3-bound proteins from U937 cells was only weakly associated with C1, but was not precipitated at all by the other RRT-SH3 domains. Although the relative intensities of these K562-and U937-derived phosphoproteins varied slightly between the experiments, similar patterns of anti-phosphotyrosine-reactive bands as shown in Fig. 3 were reproducibly observed using independent preparations of GST-SH3 proteins as well as different batches of orthovanadate-stimulated cell lysates (data not shown).
Thus, as predicted, the endogenous cellular target proteins of Hck-SH3 strongly depended in their binding on the six RT-loop residues naturally present in wild-type Hck and therefore bound much less well to the artificial RRT-SH3 domains where these residues had been changed in order to generate strong affinity for Nef.
RRT-SH3s inhibit association of Nef with PAK2
Some of the pathogenic effect of HIV-1 Nef is thought to be mediated via its association with a cellular serine kinase previously known as Nef-associated kinase (NAK; Sawai et al., 1994) and recently identified as p21-activated kinase 2 (PAK2; Renkema et al., 1999) . Although PAK2 itself does not contain an SH3 domain, association of Nef with PAK2 is dependent on the SH3 binding capacity of Nef (Manninen et al., 1998) , presumably because SH3-containing adaptor proteins are required to stabilize this complex. Efficient autophosphorylation of PAK2 bound to Nef provides an easy and sensitive readout for the ability of Nef to associate with this kinase and hence for the capability of coexpressed RRT-SH3 domains to prevent this interaction. To maximally induce the autokinase activity of PAK2 a constitutively active form of the p21 GTPase V12cdc42 was also cotransfected.
After immunoprecipitation of Nef and associated cellular proteins from the transfected cells these immunocomplexes were subjected to an in vitro kinase assay. As shown in Fig. 4 , in the absence of transfected SH3 domains an intense Nef-associated PAK2 signal was detected by IVKA. While coexpression of Hck-SH3 resulted in a partial reduction in Nef-associated PAK2 activity, the cotransfected RRT-SH3 domains (A1, A2, B4, B6, and C1) almost completely blocked formation of the Nef/ PAK2 complex. When the expression levels of Nef in cells transfected with or without an SH3 vector were examined by Western blotting analysis of either the unselected lysates or of the anti-Nef immunoprecipitates used for IVKA very similar results were obtained (data not shown). Therefore, the loss of PAK2 signal in the anti-Nef immunoprecipitates from RRT-SH3-expressing cells was not due to a failure of the anti-Nef antibody to detect Nef in complex with the RRT-SH3 domains. Thus, in agreement with the RRT-SH3/Nef coprecipitation studies (Fig. 2) , these data indicated that the RRT-SH3 domains could effectively prevent the SH3-dependent association of Nef with PAK2, an interaction that is believed to be important for the pathogenicity of Nef (Sawai et al., 1996; Wiskerchen and Cheng-Mayer, 1996) .
RRT-SH3s inhibit Nef-induced activation of NFAT
We have recently shown (Manninen et al., 2000) that Nef can activate nuclear translocation of the transcription factor NFAT (nuclear factor of activated T cells; Rao et al., 1997) . Thereby Nef can cooperate with the MAPK (mitogen-activated protein kinase)-signaling pathway in inducing gene expression via the ARRE2 element (antigen receptor responsive element of the IL-2 gene; Rao et al., 1997) . ARRE2 is a classic example of a composite NFAT/AP-1 (activator protein-1) binding site, which can be found in a number of genes involved in T cell activation (Latinis et al., 1997; Shaw et al., 1988) . Like association with PAK2, activation of NFAT-dependent transcription also correlates with the capacity of Nef for SH3 binding (Manninen et al., 2001) .
To examine the potential of the RRT-SH3 domains to inhibit NFAT activation by Nef, Jurkat T cells were cotransfected with Nef and an ARRE2-driven luciferase   FIG. 4 . RRT-SH3s inhibit PAK2 activity associated with Nef. 293T cells were transfected with Nef and SH3 expression plasmids and a dominant active V12cdc42. Equal amounts of protein lysates normalized for their protein concentration were subjected to an anti-Nef immunoprecipitation, followed by an in vitro kinase assay.
reporter plasmid together with different RRT-SH3 vectors (A1, A2, B4, B6, and C1), Hck-SH3 or the control GST vector. In addition, an elongation factor promoter-driven ␤-galactosidase expression vector was also cotransfected to confirm uniform transfection efficiency. Twenty hours after transfection the cells were stimulated with phorbol 12-myristate 13-acetate (PMA) for 4 h (to activate MAPK signaling), after which they were lysed and examined for luciferase and ␤-galactosidase activities.
When Nef was expressed together with the control GST vector NFAT activity in PMA-treated cells was increased approximately 30-fold, compared to similarly treated cells that did not express Nef (Fig. 5A) . All of the RRT-SH3 domains tested strongly reduced the NFAT activation induced by Nef ϩ PMA, resulting in the luciferase activities down to 10% of the control cells. We were first surprised to notice that despite being much less efficient in associating with Nef (Fig. 2) and in displacing Nef-bound PAK2 (Fig. 4) , Hck-SH3 was as potent as the RRT-SH3 proteins in inhibiting Nef-induced NFAT activation. Therefore, we compared the potency of Hck-SH3 and B6-SH3 in this assay by titrating the amount of SH3 vector transfected together with a constant amount of Nef and the reporter (Fig. 5B) . While confirming the dosedependent nature of NFAT inhibition, this experiment still indicated that in comparison with B6-SH3, Hck-SH3 was at least as strong as or probably a stronger inhibitor of Nef-induced NFAT activation.
Although Nef is necessary for activation of NFAT-dependent gene expression in PMA-treated Jurkat cells, it is not sufficient and many cellular signal transducing factors contribute to this increase of ARRE2-mediated transcription. Since some of these factors could be natural targets of Hck-SH3, we performed another doseresponse experiment in which we compared the potency of Hck-SH3 and B6-SH3 as inhibitors of Nef-independent NFAT activation triggered via T cell receptor ligation by anti-CD3 and anti-CD28 antibodies. As shown in Fig. 5C , transfection of B6, even in amounts that caused maximal inhibition of Nef ϩ PMA-stimulated NFAT activity, did not result in significant reduction of NFAT activity stimulated by anti-CD3/anti-CD28 antibodies. By contrast, Hck-SH3 also proved to be a relatively efficient inhibitor in this Nef-independent NFAT activation assay, resulting in 50% inhibition even when relatively small amounts of the Hck-SH3 vector were transfected.
Thus, we concluded that inhibition of Nef-induced NFAT activation by B6 was specifically caused by neutralization of Nef function and that the unexpected potency of wild-type Hck-SH3 in this assay was due to additional inhibition of parallel signaling events that support ARRE2-mediated gene expression upon activation of Jurkat cells. These results are in agreement with the data shown in Fig. 3 , indicating that the increased affinity of the RRT-SH3 domains for Nef is associated with decreased binding to cellular proteins targeted by wild-type Hck-SH3.
RRT-SH3s do not block an SH3-independent function of Nef
Downregulation of cell surface expression of the CD4 molecule is a well-characterized cellular function of Nef and involves Nef-mediated coupling of CD4 to the cellular endocytic machinery (Aiken et al., 1994) . In contrast to the two earlier discussed functions of Nef, CD4 downregulation is not dependent on SH3 binding by Nef . However, because engagement of the SH3 binding surface of Nef by an RRT-SH3 domain could affect the functionality of Nef in a more global manner, we chose also to examine the effects of RRT-SH3 expression on Nef-induced CD4 downregulation. To address this question 293T cells were transfected with plasmids expressing human CD4, green fluorescent protein (GFP), Nef, or an empty control vector, and RRT-SH3-B6 or the corresponding GST-only control vector. Forty-eight hours after transfection the cells were collected and analyzed by flow cytometry. Figure 6 shows histograms of CD4-specific fluorescence among the GFP-expressing cells (i.e., positively transfected cells) in cultures transfected with Nef, with or without B6 and in control cells (no Nef transfected).
Although the ratio of Nef vs B6-SH3 transfected was the same that gave maximal inhibition of Nef-mediated NFAT activation, the ability of Nef to induce downregulation was not significantly decreased. Thus, in agreement with the earlier mutagenesis data showing that SH3 binding is not involved in CD4 downregulation by Nef , occupancy of the SH3 binding surface of Nef by a high-affinity RRT-SH3 domain did not interfere with this function.
DISCUSSION
This study demonstrates the utility of artificial SH3 domains as inhibitors of cellular functions of the HIV-1 pathogenicity factor Nef. Recently there has been significant interest as well as success in using intracellular expression of single-chain antibodies (intrabodies) for interfering with the functions of proteins involved in the pathogenesis of cancer (Hudson, 1999) and HIV infection (Rondon and Marasco, 1997) , and this approach has been hailed as a potential tool in gene therapy for these diseases. Because of the solubility problems often associated with single-chain antibodies (Hudson, 1998; Jäger and Plückthun, 1999) as well as the potential immunogenicity of the linker peptides included in these, the use of inhibitory RRT-SH3 domains, when applicable, could be an advantageous alternative. It cannot be ruled out, however, that the amino acid changes in the RT-loops of RRT-SH3 proteins could in some cases cause similar complications.
We found that Hck-derived RRT-SH3 domains targeted for high-affinity (K D s in the range of 10 Ϫ8 to 10 Ϫ9 M; Hiipakka et al., 1999) binding to Nef could efficiently inhibit the two SH3-dependent functions of Nef, namely, recruitment of activated PAK2 kinase and activation of NFAT-dependent gene expression. By contrast, downregulation of cell surface expression of CD4, which is an exception among the cellular functions of Nef in being independent of SH3 binding, was not affected. Thus, this trans-inhibition strategy correlated well with previous studies in which the functionality of Nef has been inhibited by site-directed mutagenesis (Goldsmith et al., 1995; Saksela et al., 1995; Wiskerchen and Cheng-Mayer, 1996) . Although not observed here, it is possible that RRT-SH3 binding could also block SH3-independent functions of their target proteins by noncompetitive mechanisms, e.g., by inducing changes in protein conformation, subcellular localization, or stability. In fact, it is easy to envision strategies to modify the RRT-SH3 by attaching additional functional motifs in order to provide them with such noncompetitive inhibitory potential where this would be considered beneficial.
Besides demonstrating the inhibitory potential of the Nef-targeted RRT-SH3 proteins, this study also provides biochemical and functional support for the idea that the gain in affinity for Nef caused by the six artificial residues introduced into the RT-loop of Hck-SH3 is accompanied by a reduced binding to its normal cellular targets. Expression of Hck-SH3 was found to inhibit T cell receptortriggered activation of NFAT-dependent gene expression, whereas a Nef-targeted RRT-SH3 derivative did not interfere with this normal cellular response and instead specifically blocked only Nef-induced NFAT activation. While poor binding of the Nef-targeted RRT-SH3 domains to the natural ligands of Hck is obviously important for their use as specific intracellular inhibitors, this observation also highlights the critical role of the RT-loop in natural SH3-mediated cellular interactions.
The interface between the proline-rich SH3 binding consensus motif and its docking surface on the SH3 fold is relatively similar in different SH3/ligand complexes, which limits the maximal specificity that can be generated by modifications in the RT-loop. Thus, if expressed in sufficiently high amounts RRT-SH3 domains could also bind and inhibit random cellular SH3 binding proteins despite the mismatch of their RT-loops. However, because of the magnitude of the contribution by the RT-loop to SH3 binding affinity (Hiipakka et al., 1999; Lee et al., 1995) , it does not seem difficult to ensure a suitable level of RRT-SH3 expression, which would result in strong specific inhibition but minimal interference with other SH3-mediated cellular processes. In conclusion, our data show that intracellular expression of SH3 domains with tailored RT-loops can be used as a novel approach for inhibition of intracellular signaling events. This strategy might also be extended to other protein interaction domains where specificity/affinity determinants similar to the SH3 domain RT-loop are known. Such inhibitors should prove useful in deciphering the complex cellular signaling cascades and could provide novel tools for gene therapy as well as help to guide development of small molecular compounds with similar inhibitory properties.
MATERIALS AND METHODS
Cell cultures and transfections
293T, Jurkat (JE-6), U937, and K562 cells were obtained from ATCC and were cultured using standard procedures. 293T cells were transfected by Lipofectamine reagent (Life Technologies) and JE-6 cells by DMRIE-C transfection reagent as suggested by the supplier (Life Technologies).
Reagents
The expression vector for dominant active cdc42 (V12cdc42) and the pEBB and pEBB vector that contained a v-Src N-terminal myristoyl tail and a C-terminal HAepitope tag (pEBB-myr-HA) were kindly provided by Dr. Bruce Mayer (University of Connecticut, Farmington). The NL4-3 Nef allele R71 was cloned into the pEBB expression vector, the SH3 domains of Hck-SH3, clones A1, A2, B4, B6, and C1 (Hiipakka et al., 1999) were subcloned as GST fusions into the pEBBmyr-HA vector. The vector for SV40-CD4 was from Dr. Ned Landau (Salk Institute, La Jolla).
The Nef mouse monoclonal antibodies (2F2, 2A3, 3A2, 6.2, 2H12, 3E6, and 3F2.1) were provided by Vladimir Ovod from our institute, and the sheep polyclonal Nef antibody by Dr. Mark Harris (University of Leeds, UK). The anti-HA antibody was purchased from BabCO (Berkeley, CA), the anti-phosphotyrosine antibody PY99 from Santa Cruz (Santa Cruz, CA), anti-CD3 (HIT3a) and the phycoerythrin-conjugated anti-CD4 antibodies from Pharmingen, anti-CD28 monoclonal antibody from CLB (Amsterdam, Netherlands), biotinylated anti-mouse IgG from DAKO, biotinylated streptavidin-horseradish peroxidase conjugate from Amersham Pharmacia Biotech, and anti-goat/sheep IgG-AP GT34 conjugate from Sigma.
Expression and purification of GST and GST-SH3 were carried out as previously described (Hiipakka et al., 1999) .
Detection of transfected proteins
293T cells were harvested 48 h after transfection, washed with standard phosphate-buffered saline (PBS), and lysed in in vitro kinase assay lysis buffer (IVKA lysis buffer; 50 mM HEPES, pH 7.4, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EGTA, 1.5 mM MgCl 2 , 10 mM NaF, 1 mM Na-orthovanadate 1 mM phenylmethylsulfonyl fluoride (PMSF), and 10 g/ml aprotinin). Lysates (1 mg of total cellular protein) were incubated with glutathione Sepharose 4B beads (Amersham Pharmacia Biotech) for 4 h at 4°C and washed with IVKA lysis buffer. The proteins were separated by SDS-PAGE followed by immunoblotting done as described previously (Manninen et al., 1998) .
For IVKA the monoclonal 2F2 Nef antibody was incubated with 500 g of total cellular protein and protein G-Sepharose beads (Sigma) for 4 h at 4°C. After washing three times with IVKA lysis buffer and twice with kinase assay buffer (50 mM HEPES, pH 7.4, and 5 mM MgCl 2 ) [␥-32 P]ATP (2.5 Ci; Amersham Pharmacia Biotech) was added to the immunoprecipitates followed by a 30-min incubation at 37°C. The beads were washed with ice-cold PBS and boiled in Laemmli sample buffer, followed by SDS-PAGE and exposure on BioMax MR film (Kodak).
The reagents and protocols used for the luciferase assays were exactly as described previously (Manninen et al., 2000) .
For the CD4 downregulation assay 293T cells were cotransfected with human CD4 and GFP alone or together with Nef R71 and B6. Forty-eight hours after transfection the cells were harvested and washed with PBS ϩ 0.1% BSA and stained with PE-conjugated anti-human CD4 (dilution 1:10) for 30 min. After two washes with PBS ϩ 0.1% BSA the stained cells were suspended in PBS ϩ 0.5 mM EDTA. The CD4 surface expression among the GFP-positive cells was examined using FACScan (Becton-Dickinson).
K562 and U937 cells were stimulated by pervanadate as described in Jin et al. (1999) . The lysates were preincubated with recombinant GST protein (10 g/mg total protein) at 4°C for 2 h, followed by capture on glutathione Sepharose 4B beads. These precleared lysates were split into aliquots corresponding to 500 g of total cellular protein and incubated for 2 h at 4°C with beads coated with 8 g of GST or GST-SH3. The beads were washed three times with Nonidet P-40 lysis buffer (1% Nonidet P-40, 150 mM NaCl, 20 mM Tris-Cl, pH 7.4, 0.5% sodium deoxycholate, 50 mM NaF, 1 mM PMSF, and 10 g/ml aprotinin) and once with PBS and boiled in Laemmli sample buffer, followed by SDS-PAGE and antiphosphotyrosine immunoblotting.
